A detailed history of Ubs Group Ag transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 13,228 shares of BTAI stock, worth $5,423. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,228
Previous 52,483 74.8%
Holding current value
$5,423
Previous $67,000 88.06%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.53 - $1.34 $20,805 - $52,601
-39,255 Reduced 74.8%
13,228 $8,000
Q2 2024

Aug 13, 2024

SELL
$1.14 - $2.97 $107,928 - $281,181
-94,674 Reduced 64.34%
52,483 $67,000
Q1 2024

May 13, 2024

BUY
$1.95 - $4.04 $192,732 - $399,301
98,837 Added 204.55%
147,157 $414,000
Q4 2023

Feb 09, 2024

SELL
$2.32 - $5.51 $70,258 - $166,864
-30,284 Reduced 38.53%
48,320 $142,000
Q3 2023

Nov 09, 2023

SELL
$2.49 - $11.85 $80,506 - $383,134
-32,332 Reduced 29.14%
78,604 $198,000
Q2 2023

Aug 11, 2023

SELL
$6.39 - $28.58 $315,365 - $1.41 Million
-49,353 Reduced 30.79%
110,936 $738,000
Q1 2023

May 12, 2023

BUY
$17.7 - $33.24 $373,027 - $700,533
21,075 Added 15.14%
160,289 $2.99 Million
Q4 2022

Feb 08, 2023

SELL
$10.25 - $22.43 $42,783 - $93,622
-4,174 Reduced 2.91%
139,214 $2.99 Million
Q3 2022

Nov 10, 2022

BUY
$11.19 - $17.89 $295,057 - $471,723
26,368 Added 22.53%
143,388 $1.7 Million
Q2 2022

Aug 10, 2022

SELL
$9.03 - $21.55 $573,802 - $1.37 Million
-63,544 Reduced 35.19%
117,020 $1.54 Million
Q1 2022

May 16, 2022

SELL
$15.0 - $22.83 $290,535 - $442,194
-19,369 Reduced 9.69%
180,564 $3.78 Million
Q4 2021

Feb 14, 2022

SELL
$20.12 - $35.09 $317,735 - $554,141
-15,792 Reduced 7.32%
199,933 $4.06 Million
Q3 2021

Nov 15, 2021

BUY
$23.84 - $32.03 $1.31 Million - $1.77 Million
55,122 Added 34.32%
215,725 $6.55 Million
Q2 2021

Aug 13, 2021

SELL
$29.06 - $38.83 $1.07 Million - $1.43 Million
-36,766 Reduced 18.63%
160,603 $4.67 Million
Q1 2021

May 12, 2021

BUY
$39.04 - $64.6 $4.12 Million - $6.81 Million
105,420 Added 114.65%
197,369 $8.52 Million
Q4 2020

Feb 11, 2021

BUY
$42.46 - $56.58 $171,793 - $228,922
4,046 Added 4.6%
91,949 $4.25 Million
Q3 2020

Nov 12, 2020

BUY
$37.44 - $64.63 $263,165 - $454,284
7,029 Added 8.69%
87,903 $3.81 Million
Q2 2020

Jul 31, 2020

SELL
$17.62 - $58.71 $99,746 - $332,357
-5,661 Reduced 6.54%
80,874 $4.29 Million
Q1 2020

May 01, 2020

SELL
$12.26 - $41.14 $80,290 - $269,425
-6,549 Reduced 7.04%
86,535 $1.93 Million
Q4 2019

Feb 14, 2020

BUY
$4.05 - $14.61 $53,387 - $192,589
13,182 Added 16.5%
93,084 $1.36 Million
Q3 2019

Nov 14, 2019

BUY
$7.04 - $11.77 $30,553 - $51,081
4,340 Added 5.74%
79,902 $563,000
Q2 2019

Aug 14, 2019

BUY
$8.99 - $11.79 $4,270 - $5,600
475 Added 0.63%
75,562 $828,000
Q1 2019

May 14, 2019

BUY
$3.49 - $10.47 $217,657 - $652,972
62,366 Added 490.26%
75,087 $743,000
Q4 2018

Feb 14, 2019

BUY
$2.41 - $7.61 $21,244 - $67,082
8,815 Added 225.68%
12,721 $49,000
Q3 2018

Nov 14, 2018

BUY
$7.51 - $12.99 $5,332 - $9,222
710 Added 22.22%
3,906 $30,000
Q2 2018

Aug 14, 2018

BUY
$7.02 - $11.26 $3,748 - $6,012
534 Added 20.06%
3,196 $29,000
Q1 2018

May 15, 2018

BUY
$9.83 - $11.03 $26,167 - $29,361
2,662 New
2,662 $27,000

Others Institutions Holding BTAI

About BioXcel Therapeutics, Inc.


  • Ticker BTAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,022,500
  • Market Cap $11.5M
  • Description
  • BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...
More about BTAI
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.